Investors sold shares of Gilead Sciences Inc. (NASDAQ:GILD) on strength during trading hours on Wednesday. $118.27 million flowed into the stock on the tick-up and $188.67 million flowed out of the stock on the tick-down, for a money net flow of $70.40 million out of the stock. Of all companies tracked, Gilead Sciences had the 0th highest net out-flow for the day. Gilead Sciences traded up $1.22 for the day and closed at $86.66

A number of equities analysts have weighed in on the stock. Zacks Investment Research lowered shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 4th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Gilead Sciences in a research report on Saturday, May 14th. Jefferies Group reiterated a “hold” rating and issued a $96.00 price target on shares of Gilead Sciences in a research report on Wednesday, June 29th. Royal Bank Of Canada reiterated a “buy” rating on shares of Gilead Sciences in a research report on Saturday, April 30th. Finally, Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $104.36 price target for the company in a research report on Thursday, March 24th. Seven investment analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Gilead Sciences has an average rating of “Buy” and an average price target of $114.05.

The firm has a market cap of $115.42 billion and a P/E ratio of 7.40. The stock has a 50-day moving average of $84.65 and a 200 day moving average of $89.11.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 28th. The biopharmaceutical company reported $3.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.13 by $0.10. The business had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $8.08 billion. The firm’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.94 earnings per share. On average, equities analysts anticipate that Gilead Sciences Inc. will post $12.02 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Wednesday, June 29th. Shareholders of record on Thursday, June 16th were paid a dividend of $0.47 per share. The ex-dividend date of this dividend was Tuesday, June 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a yield of 2.17%.

In other news, EVP Paul Rutherford Carter sold 2,000 shares of Gilead Sciences stock in a transaction on Monday, May 2nd. The stock was sold at an average price of $88.72, for a total transaction of $177,440.00. Following the transaction, the executive vice president now owns 62,939 shares in the company, valued at approximately $5,583,948.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Chairman John C. Martin sold 100,000 shares of Gilead Sciences stock in a transaction on Monday, May 2nd. The stock was sold at an average price of $87.82, for a total value of $8,782,000.00. Following the transaction, the chairman now owns 4,119,727 shares in the company, valued at approximately $361,794,425.14. The disclosure for this sale can be found here.

Several hedge funds and institutional investors recently bought and sold shares of the company. Adirondack Trust Co. raised its position in Gilead Sciences by 6.2% in the fourth quarter. Adirondack Trust Co. now owns 12,500 shares of the biopharmaceutical company’s stock valued at $1,037,000 after buying an additional 729 shares in the last quarter. Sfmg LLC raised its position in Gilead Sciences by 5.2% in the fourth quarter. Sfmg LLC now owns 10,619 shares of the biopharmaceutical company’s stock valued at $1,075,000 after buying an additional 522 shares in the last quarter. NEXT Financial Group Inc raised its position in Gilead Sciences by 1.7% in the fourth quarter. NEXT Financial Group Inc now owns 10,889 shares of the biopharmaceutical company’s stock valued at $1,101,000 after buying an additional 183 shares in the last quarter. Parsec Financial Management Inc. raised its position in Gilead Sciences by 121.1% in the fourth quarter. Parsec Financial Management Inc. now owns 10,905 shares of the biopharmaceutical company’s stock valued at $1,103,000 after buying an additional 5,972 shares in the last quarter. Finally, Farmers & Merchants Investments Inc. raised its position in Gilead Sciences by 8,897.6% in the fourth quarter. Farmers & Merchants Investments Inc. now owns 11,337 shares of the biopharmaceutical company’s stock valued at $1,147,000 after buying an additional 11,211 shares in the last quarter.

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.